Fierce Pharma

JULY 27, 2023

scored a legal win in the insurance case tied to the 2017 "NotPetya" cyberattack, the case is in appeals—again. scored a legal win in the insurance case tied to the 2017 "NotPetya" cyberattack, the case is in appeals—again. About a month and a half after Merck & Co. That didn't take long.

Insurance 200

Insurance 200

Fierce Pharma

JANUARY 24, 2024

Apotex and two of its generics peers have agreed to settle with direct purchasers of their drugs in a price-fixing case that stretches all the way back to 2017. Over the years, myriad generic drugmakers have had to ante up fines and settlement fees for allegedly colluding on the prices of copycat drugs.

168

168

Pharmacy Times

SEPTEMBER 14, 2023

The act would have permitted health care facilities to stock up on compounded medications without forcing the supplying 503A pharmacies to register as outsourcing facilities.

Medical 55

Medical Patients 55

Fierce Pharma

AUGUST 22, 2023

Ingrezza was first approved in tardive dyskinesia in 2017. With a new FDA approval to rival Teva's Austedo, Neurocrine Biosciences’ Ingrezza is debuting in a treatment area with hundreds of millions of dollars of revenue potential. | The FDA approved Ingrezza capsules to treat adult with chorea associated with Huntington’s disease.

FDA 240

FDA Pharmaceutical 240

Fierce Pharma

MAY 31, 2023

After an investigation that dates back to 2017, four former Novartis executives and a Greek politician were cleared of bribery charges. After a yearslong investigation involving politicians and medical professionals alike, Novartis is looking to close the books on its Greek bribery imbroglio.

Doctors 247

Doctors Medical 247

Fierce Pharma

AUGUST 31, 2023

Bill Sibold, who took over the company's specialty care unit in 2017 just after Dupixent's first approval, is leaving Sanofi effective immediately. For six years, Sanofi's specialty care chief Bill Sibold has helped the company make the most of its Regeneron-partnered immunology superstar Dupixent.

244

244

Fierce Pharma

NOVEMBER 20, 2023

Patients with ultra-rare desmoid tumors now have an FDA-approved treatment, thanks to a drug made by SpringWorks Therapeutics, which spun out of Pfizer in 2017 with a portfolio of rare disease candidates. Thanks to a new FDA approval, patients with ultra-rare desmoid tumors now have an FDA-approved treatment.

FDA 176

FDA Patients 176

Fierce Pharma

JUNE 27, 2023

Equal Employment Opportunity Commission, which sued the company in September over claims it had changed its hiring preferences in 2017 to prioritize recruitment of more millennials to its workforce. . | Eli Lilly will pay out $2.4 million as part of a settlement agreement with the U.S.

Recruitment 219

Recruitment 219

Fierce Pharma

JULY 5, 2023

Since 2017, the company has sold off three PRVs—getting less in return for each successive sale. While the price of just about everything has increased over the last six years in the U.S., the same can’t be said for the cost of an FDA priority review voucher. Just ask Sarepta Therapeutics. | The price of priority review vouchers is falling.

FDA 233

FDA Sales 233

pharmaphorum

APRIL 8, 2024

Less than half of the cancer therapies given accelerated approval by the FDA in 2013 to 2017 showed a clinical benefit in a confirmatory trial within the next five years

FDA 90

FDA 90

The Brooks Group

DECEMBER 4, 2017

We’ve rounded up the top 10 most popular posts from The Sales Leader blog in 2017 to give you a place to start when you’re looking to improve your team’s performance. Top 10 Sales Effectiveness Articles from 2017. 4 Step Action Plan for Sales Target Achievement.

Sales 61

Sales Prospecting Sales Management Sales territory 61

MedCity News

JUNE 28, 2023

in 2017. An Evernorth study found that in 2021, 25% of adults with ADHD did not receive any treatment, though this is a decrease from 38.5% About 21.4% of adults with ADHD received both medication and behavioral therapy in 2021, up from 12.9%

Medical 101

Medical 101

Pharmaceutical Technology

NOVEMBER 28, 2023

Venture financing for innovative radiopharmaceutical drugs witnessed an approximately 550% increase from $63m in 2017 to $408m in 2023 YTD (year-to-date) total deal value in the US.

98

98

The Brooks Group

DECEMBER 27, 2017

2017 was a big year for The Brooks Group. 2017 was the year of the sales training revolution, with the world-renowned IMPACT Selling being released in an eLearning platform, IMPACT-U® ! 2017 heard quite a few gong rings! The entire team at The Brooks Group is feeling motivated and charged up after such a strong 2017.

Training 40

Training Sales Sales goal Consulting 40

World of DTC Marketing

MARCH 31, 2022

Between 2017 and 2019, pharmacy benefit managers’ gross profit increased by 12 percent despite PBM retention of manufacturer rebates decreasing during this period, according to a report released on Dec. The report showed that the PBM gross profit increased from $25 billion to $28 billion between 2017 and 2019.

Insurance 240

Insurance Prescription Manufacturing Sales 240

MedCity News

JULY 28, 2022

Attorney General Letitia James accused CVS of a scheme starting in 2017 to prevent New York safety net hospitals from using the company of their choice to obtain federal drug subsidies on prescriptions filled at CVS through the 340B program.

Prescription 138

Prescription Safety 138

MedCity News

APRIL 10, 2023

The share of traditional Medicare enrollees who bought Medicare Supplement coverage rose to 41% in 2021, compared to 35% in 2017, according to a report from America’s Health Insurance Plans. Medicare Supplement enrollees are three times less likely to have issues paying medical bills than those who only have traditional Medicare.

Insurance 107

Insurance Medical 107

European Pharmaceutical Review

NOVEMBER 21, 2022

A study on the surge of new antimicrobial research has shown that despite almost a quarter of a million research papers (227,808) being published on the 12 bacterial families in the World Health Organization (WHO) global priority pathogen list of antibiotic-resistant bacteria from 2017, no new class of antibiotics has gone to market since 1987.

Management 87

Management Leads Pharmaceutical Marketing 87

World of DTC Marketing

FEBRUARY 17, 2022

In recent years, early detection and treatment improvements have helped boost the 3-year survival rate for lung cancer from 21% in 2004 to 31% in 2015 through 2017. In recent years, early detection and treatment improvements have helped boost the 3-year survival rate for lung cancer from 21% in 2004 to 31% in 2015 through 2017.

Insurance 271

Insurance Medicine Leads Medical 271

PharmExec

MARCH 7, 2024

Besponsa (inotuzumab ozogamicin) was initially approved in August 2017 for adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.

Patients 40

Patients FDA 40

Pharmacy Times

APRIL 11, 2024

Benralizumab was previously approved by the FDA in 2017 as an add-on maintenance therapy for patients 12 years and older.

FDA 44

FDA Patients 44

MedCity News

DECEMBER 5, 2022

Of this group, 50% provide these benefits through a Medicare Advantage plan, up from 26% in 2017. Currently, only 13% of large employers — or companies with 200 or more employees — offer retiree health benefits, the Kaiser Family Foundation survey found.

93

93

Clarivate

SEPTEMBER 18, 2023

As a pioneer in automated indexing and retrieval of information since 1955, Eugene Garfield (1925-2017) developed citation databases for science that changed how researchers search and assess the scholarly literature.

Specialization 119

Specialization Networking Leads Professional Services 119

MedCity News

JULY 7, 2022

From 2001 to 2017, the fatal overdose rate in Cabell County increased from 16.6 per 100,000. Judge finds no evidence of causation.

Biopharma 103

Biopharma Healthcare Healthcare 103

Pharmaceutical Technology

DECEMBER 18, 2023

The latest $389m pledge follows an initial investment of $300m in 2017 that was raised to fund early-stage life-science startups.

Pharmaceutical 52

Pharmaceutical 52

Clarivate

APRIL 14, 2022

Our research shows that Ukraine has contributed more than 5,000 scientific publications towards the UN Sustainable Development Goals since 2017, including on peace and justice initiatives (SDG-16). According to our data, Ukraine contributed a total of 5,863 scientific publications towards SDGs since 2017 (see figure 2).

Government 133

Government Education Distribution Food 133

MedCity News

AUGUST 28, 2022

The biotech company had been collaborating with Takeda Pharmaceutical since 2017. The agreement termination means that two preclinical microbiome therapy candidates for inflammatory bowel disease will now return to Finch Therapeutics.

Pharmaceutical 82

Pharmaceutical Biopharma Pharma 82

Pharmaceutical Technology

OCTOBER 5, 2023

Antibody-drug conjugates (ADCs) saw a 400% growth in total licensing agreement deal value from 2017 to 2022 and reached a peak of $16.6bn.

52

52

Clarivate

APRIL 21, 2022

As can be seen from Figure 1, between 2017-2021, Ukraine’s research output focused on macro topics such as physics (19%), clinical and life sciences (16%), chemistry (16%), social sciences (12%), engineering and material sciences (10%), and electrical engineering (10%) with a total of 52,618 papers published. Source: InCites.

Engineering 98

Engineering Education Electronics Medicine 98

European Pharmaceutical Review

DECEMBER 1, 2023

Additionally, given implementation of the latest EU regulations applicable to medical devices (2017/745 and 2017/746) is “still in its early stages”, there is little information on the impact of these regulations in addressing the falsified medical devices.

Medical 83

Medical Pharmaceutical 83

PharmaTech

MAY 16, 2023

The first CleanCap analog was launched in 2017, and since then, the capping technology has been incorporated in one of the first commercially approved COVID-19 vaccines.

52

52

Pharmacy Times

DECEMBER 21, 2023

The cost of defending license matters and malpractice claim costs have increased over a 5-year period (2017-2022).

52

52

PharmExec

NOVEMBER 14, 2023

The FDA granted accelerated approval to Aliqopa in September 2017 for the treatment of adults with relapsed follicular lymphoma previously treated with at least two prior systemic therapies.

Marketing 52

Marketing FDA 52

PharmaTech

AUGUST 10, 2023

The initial collaboration between the two companies began in 2017 with an extension announced in 2021.

Pharmaceutical 52

Pharmaceutical 52

European Pharmaceutical Review

APRIL 8, 2024

Janssen), a Johnson & Johnson company in December 2017. The benefit of the cilta-cel infusion was observed when compared to standard of care continuous therapy in patients who relapsed after one to three prior treatments, Dr Sidana added, Legend Biotech entered into a license and collaboration agreement with Janssen Biotech, Inc.

Food and Drug Administration 94

Food and Drug Administration FDA Medicine Physicians 94

PharmaTech

DECEMBER 20, 2022

This article focuses on drawing parallels between ICH Q14/Q2(R2), United States Pharmacopeia (USP) , and International Organization for Standardization/International Electrotechnical Commission (ISO/IEC) 17025:2017.

52

52

World of DTC Marketing

OCTOBER 21, 2021

The analysis focused on Medicare Part B and Part D spending — which covers outpatient medical care and prescription drugs, respectively, — in 2017, 2018 and 2019, the researchers said.

FDA 234

FDA Insurance Prescription Medicine 234